Drug Patents owned by Therapeuticsmd Inc

1. List of Annovera drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10780047 THERAPEUTICSMD INC Method of providing birth control
Feb, 2039

(15 years from now)

US10632066 THERAPEUTICSMD INC Method of providing birth control
Feb, 2039

(15 years from now)

US10765628 THERAPEUTICSMD INC Method of providing birth control
Feb, 2039

(15 years from now)

US10940157 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(16 years from now)

US11529308 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(16 years from now)

US10918649 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(16 years from now)

US10925882 THERAPEUTICSMD INC System for providing birth control
Jun, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 10, 2023

Drugs and Companies using ETHINYL ESTRADIOL; SEGESTERONE ACETATE ingredient

NCE-1 date: 2022-08-10

Market Authorisation Date: 10 August, 2018

Treatment: Method of contraception by inserting a vaginal system for up to 13 21/7-day (in/out) cycles, wherein efficacy requires the system cannot be out of the vagina for more than 2 cumulative hours in any such cycle without using alternative contraception; Method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg ethinyl estradiol into a vagina for up to thirteen 21/7-day (in/out) cycles

Dosage: RING;VAGINAL

More Information on Dosage

ANNOVERA family patents

11

United States

1

Korea, Republic of

1

Japan

1

Colombia

1

Israel

1

Chile

1

Australia

1

Argentina

1

Canada

1

China

1

Brazil

1

European Union

2. List of Bijuva drug patents

BIJUVA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033626 THERAPEUTICSMD INC Progesterone formulations having a desirable pk profile
Nov, 2032

(9 years from now)

US10639375 THERAPEUTICSMD INC Progesterone formulations
Nov, 2032

(9 years from now)

US11110099 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US8993548 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US11103516 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US10206932 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US8846649 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US8846648 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US9114146 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US9114145 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US10675288 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US9301920 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US8987237 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US9006222 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US10806740 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US11103513 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US8933059 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US11166963 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US8633178 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US10052386 THERAPEUTICSMD INC Progesterone formulations
Nov, 2032

(9 years from now)

US8993549 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient

Market Authorisation Date: 28 October, 2018

Treatment: Treatment of menopause symptoms, including vasomotor symptoms

Dosage: CAPSULE;ORAL

How can I launch a generic of BIJUVA before it's patent expiration?
More Information on Dosage

BIJUVA family patents

97

United States

20

Australia

18

Japan

13

European Union

11

Korea, Republic of

11

Canada

10

Mexico

8

Russia

8

Brazil

5

Argentina

4

Israel

2

Spain

2

Croatia

2

Hungary

2

Poland

1

Portugal

1

South Africa

1

Lithuania

1

RS

3. List of Imvexxy drug patents

IMVEXXY's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10537581 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(9 years from now)

US11246875 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(9 years from now)

US11241445 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(9 years from now)

US10835487 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(9 years from now)

US9289382 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(9 years from now)

US10806697 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(9 years from now)

US11351182 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(9 years from now)

US11304959 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(9 years from now)

US11497709 THERAPEUTICSMD INC NA
Nov, 2032

(9 years from now)

US10471072 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Jun, 2033

(10 years from now)

US10568891 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Jun, 2033

(10 years from now)

US10888516 THERAPEUTICSMD INC Soluble estradiol capsule for vaginal insertion
Jun, 2033

(10 years from now)

US10668082 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Jun, 2033

(10 years from now)

US11116717 THERAPEUTICSMD INC Soluble estradiol capsule for vaginal insertion
Jun, 2033

(10 years from now)

US11065197 THERAPEUTICSMD INC Soluble estradiol capsule for vaginal insertion
Jun, 2033

(10 years from now)

US11123283 THERAPEUTICSMD INC Soluble estradiol capsule for vaginal insertion
Jun, 2033

(10 years from now)

US10258630 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Dec, 2033

(10 years from now)

US9180091 THERAPEUTICSMD INC Soluble estradiol capsule for vaginal insertion
Dec, 2033

(10 years from now)

US10398708 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Dec, 2033

(10 years from now)

US11266661 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Feb, 2034

(10 years from now)

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 29 May, 2018

Treatment: Treatment of dyspareunia; Treatment of a symptom of vulvar and vaginal atrophy; Treatment of moderate to severe dyspareunia

Dosage: INSERT;VAGINAL

How can I launch a generic of IMVEXXY before it's patent expiration?
More Information on Dosage

IMVEXXY family patents

92

United States

19

Australia

17

Japan

12

European Union

10

Korea, Republic of

10

Canada

9

Mexico

8

Brazil

7

Russia

4

Argentina

4

Israel

2

Spain

2

Croatia

2

Hungary

2

Poland

1

Portugal

1

South Africa

1

Lithuania

1

RS

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in